TSTickerStarGet alerts

MPLT 10-Q filed 2026-11-16 | Key takeaways

MPLT filed its 10-Q; the most relevant disclosure change is added August 2026 Private Placement: On August 13, 2026, the Company entered into a Securities Purchase Agreement with certain institutional investors and closed the 2026 Private Placement on August 14, 2026, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 s.

Share this story

Key takeaways

  • August 2026 private placement raised $140.1M net proceeds; Catalyst purchased $83.4M and Forbion purchased $8.6M of the total $92M from related parties

  • Phase 2 ZEPHYR trial for ML-007C-MA in schizophrenia announced positive topline results in July 2026; FDA end-of-phase 2 meeting planned

  • Phase 2 IRIS trial for ML-004 in autism spectrum disorder did not meet primary endpoint in June 2026

  • Phase 2 VISTA trial for ML-007C-MA in Alzheimer's disease psychosis ongoing; topline results expected H2 2027

  • Cash, cash equivalents and investments of $463.4M as of September 30, 2026, versus $351.3M as of June 30, 2026

  • Accumulated deficit widened to $533.0M as of September 30, 2026, from $481.4M as of June 30, 2026

  • Vanderbilt Agreement amended in September 2026; one-time $0.4M payment made; aggregate milestone obligations revised to up to $52.0M

Key metrics

Net loss - Q3 2026three months ended September 30, 2026
$51.6 million$22.2 million increase in net loss
Net loss - Nine months 2026nine months ended September 30, 2026
$172.5 million$90.9 million increase in net loss
Net loss per share - Q3 2026three months ended September 30, 2026
-$0.97per share improvement from -$37.18 due to reverse stock split
Net loss per share - Nine months 2026nine months ended September 30, 2026
-$3.60per share improvement from -$105.70 due to reverse stock split
Net cash used in operating activities - Nine months 2026nine months ended September 30, 2026
$131.7 million$40.4 million increase in cash used
Cash, cash equivalents and investmentsSeptember 30, 2026
$463.4 million
Shares outstandingSeptember 30, 2026
55,669,897
Accumulated deficitSeptember 30, 2026
$533.0 million

Disclosure changes

  • August 2026 Private Placement

    On August 13, 2026, the Company entered into a Securities Purchase Agreement with certain institutional investors and closed the 2026 Private Placement on August 14, 2026, selling 9,197,887 shares of common stock and pre-funded warrants to purchase 3,983,168 shares for net proceeds of $140.1 million, after deducting $10.0 million in placement agent fees and offering expenses. Related parties Catalyst and Forbion participated, purchasing approximately $92.0 million of the offering. Registration rights agreement r...

    Major equity financing that significantly increased cash position and provides runway through 2028; related party participation indicates insider confidence; dilution to existing shareholders.
  • Phase 2 Clinical Trial Results - ML-007C-MA Schizophrenia

    In July 2026, the Company announced positive topline results from ZEPHYR, a Phase 2 trial evaluating ML-007C-MA for treatment of schizophrenia. The Company intends to engage with FDA in an end-of-Phase 2 meeting to discuss the path forward, including design of a Phase 3 trial intended to support an initial NDA submission.

    Positive Phase 2 results represent significant clinical milestone and path toward potential regulatory approval.
  • Phase 2 Clinical Trial Results - ML-004 ASD

    In June 2026, the Company announced topline results from IRIS, a Phase 2 trial evaluating ML-004 for treatment of social communication deficit and/or irritability in autism spectrum disorder. The trial did not meet its primary endpoint. The Company intends to engage with FDA in an end-of-Phase 2 meeting to determine next steps, including potential strategic collaborations.

    Phase 2 trial failure for ML-004 is a negative clinical development outcome that may affect future pipeline value.
  • Vanderbilt License Agreement Amendment

    In September 2026, the Company entered into an amendment to the Vanderbilt Agreement. The amendment required a one-time payment of $0.4 million, revised certain development milestones, reduced aggregate milestone payment obligations from $52.4 million to up to $52.0 million, and revised sublicensing revenue sharing terms with percentages ranging from 2% to 50% depending on development stage at sublicense grant.

    Amendment modifies milestone obligations and sublicensing terms; $0.4 million payment was accrued and paid in October 2026.
  • South San Francisco Lease

    In June 2026, the Company entered into a 7-year lease for office and laboratory space in South San Francisco, California, with an option to extend for an additional 5 years. The lease has not yet commenced; expected to begin May 2027 subject to landlord tenant improvements. Total lease payments from October 2026 through end of lease term total $13.4 million.

    New lease commitment represents future contractual obligation of $13.4 million; reflects Company's expansion of facilities.
  • Redwood City Lease Early Termination

    In June 2026, the Company exercised the early termination option for its Redwood City, California lease, providing required 15-month notice to the lessor. The lease end date changed from June 2031 to September 2027. During the nine months ended September 30, 2026, the Company derecognized a right-of-use asset and lease liabilities of $3.4 million due to the term change.

    Early termination reduces long-term lease obligations but results in non-cash derecognition charge; lease payments through September 2027 total $1.0 million.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow MPLT in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert